» Articles » PMID: 29362121

Treatment Outcomes of Nasopharyngeal Carcinoma in Modern Era After Intensity Modulated Radiotherapy (IMRT) in Hong Kong: A Report of 3328 Patients (HKNPCSG 1301 Study)

Overview
Journal Oral Oncol
Publisher Elsevier
Specialty Dentistry
Date 2018 Jan 25
PMID 29362121
Citations 109
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To evaluate treatment outcomes, failure patterns and late toxicities in patients with nasopharyngeal carcinoma (NPC) treated by intensity modulated radiotherapy (IMRT) in 6 public hospitals in Hong Kong over a 10-year period from 2001 to 2010.

Material And Methods: Eligible patients were identified through the Hong Kong Cancer Registry data base. Clinical information was retrieved and verified by oncologists working in the individual centers. Treatment details, survival outcomes and late toxicities were analyzed.

Results: A total of 3328 patients were recruited. The median follow-up time was 80.2 months. The 8-year actuarial overall survival (OS), local failure-free survival (LFFS), regional failure-free survival (RFFS), distant failure free survival (DFFS), progression-free survival (PFS) for the whole group was 68.5%, 85.8%, 91.5%, 81.5% and 62.6% respectively. Male gender, older age, advanced T and N stage were adverse prognostic factors for OS, DFFS and PFS, whereas use of chemotherapy in form of concurrent chemo-irradiation (CRT), neoadjuvant + CRT, or CRT + adjuvant chemotherapy were favorable prognostic factors for OS and PFS. The local control was adversely affected by advanced T stage. N stage remained as the single adverse prognostic factor for regional control. Distant metastasis was the commonest site of failure.

Conclusion: IMRT is an effective treatment for NPC with excellent overall loco-regional control. Distant metastasis is the major site of failure. Concurrent chemotherapy with cisplatin has an established role in NPC patients treated by IMRT.

Citing Articles

Long-term results of locoregionally advanced nasopharyngeal carcinoma treated with cisplatin and 5-fluorouracil induction chemotherapy with or without docetaxel in young and middle aged adults.

Zheng Y, Xue F, Ou D, Niu X, Hu C, He X J Cancer Res Clin Oncol. 2025; 151(3):99.

PMID: 40035865 PMC: 11880137. DOI: 10.1007/s00432-025-06145-6.


Clinical Outcomes for Nasopharyngeal Cancer in Non-Asian Patients: A Single-Center Experience.

Zahu R, Urian D, Manolescu V, Ungureanu A, Bodale C, Iacob A J Clin Med. 2025; 14(4).

PMID: 40004708 PMC: 11856680. DOI: 10.3390/jcm14041177.


Pretreatment FDG PET in prognosis of locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiation therapy.

Niu X, Xue F, Ou D, Zheng Y, Hu C, Shen C Int J Med Sci. 2025; 22(4):933-939.

PMID: 39991768 PMC: 11843132. DOI: 10.7150/ijms.105995.


METTL3-mediated m6A modification of SLC7A11 enhances nasopharyngeal carcinoma radioresistance by inhibiting ferroptosis.

Dai Z, Lin B, Qin M, Lin Y, Wang L, Liao K Int J Biol Sci. 2025; 21(4):1837-1851.

PMID: 39990661 PMC: 11844296. DOI: 10.7150/ijbs.100518.


Gemcitabine and cisplatin induction chemotherapy followed by concurrent chemoradiotherapy for stage III-IVA nasopharyngeal carcinoma: A real-world study.

Van D, Viet S, Phu G Sci Prog. 2025; 108(1):368504241312582.

PMID: 39885780 PMC: 11783467. DOI: 10.1177/00368504241312582.